Just a moment, the page is loading...
Browse ALL STUDIES
Keyword Search
View All Selected
Clear All
Login / Create Account
Login
Create Account
Home
About Us
Privacy Policy
Minimum System Requirements
How To Join
Mission
Data Sponsors
Researchers
How It Works
How to Request Data
Review of Requests
Data Sharing Agreement
Access to Data
Independent Review Panel
Metrics
FAQs
News
Help/Contact Us
The effects of maraviroc versus efavirenz in combination with zidovudine/abacavir on the CD4/CD8 ratio in treatment-naïve HIV-infected individuals.
Proposal
1079
Title of Proposed Research
The effects of maraviroc versus efavirenz in combination with zidovudine/abacavir on the CD4/CD8 ratio in treatment-naïve HIV-infected individuals.
Lead Researcher
Sergio Serrano-Villar, MD PhD
Affiliation
Deparment of Infectious DiseasesUniversity Hospital Ramón y CajalMadrid, Spain.
Funding Source
None
Potential Conflicts of Interest
Lead Researcher: None
Researcher 1: SM has received grants and consulting fee from ViiV-Healthcare
Researcher 2: None
Management of Real or Potential Conflicts of Interest
Any potential conflict of interest will be disclosed when data are presented and published.
Data Sharing Agreement Date
12 October 2014
Lay Summary
A low CD4/CD8 ratio is considered a surrogate marker of immunosenescence and is an independent predictor of all-cause mortality. We have recently described in long-term virally suppressed HIV infected subjects a negative correlation between the CD4/CD8 ratio and inflammation/inmmunosenescence. We also observed that is independently associated with surrogate markers of age-associated disease and non-AIDS-related morbidity and mortality. Collectively, these studies suggest that a low CD4/CD8 ratio despite otherwise effective ART might identify a new clinical phenotype of patients needed of novel interventions. Given the strong clinical implications the impact of different regimens on the CD4/CD8 ratio recovery needs to be analyzed. For this purpose, we herein request the MERIT study, a randomized, double-blind, multicenter phase IIb/III study with an open-label extension phase (240-week follow-up) to assess the efficacy of zidovudine/lamivudine in combination with maraviroc or efavirenz in treatment-naïve patients.
Study Data Provided
[{ "PostingID": 1406, "Title": "VIIV-A4001026", "Description": "Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine
Medicine: maraviroc, Condition: Infection, Human Immunodeficiency Virus, Phase: 3, Clinical Study ID: A4001026, Sponsor: ViiV" }]
Statistical Analysis Plan
For the principal objective, longitudinal changes in CD4 and CD8 counts and in the CD4/CD8 ratio will be assessed using linear mixed models with random intercepts. Age, gender, risk factors for HIV acquisition, year of ART initiation, baseline CD4+ T-cell count and CD8+ T-cell will be included in multivariate analyses as fixed-effects. Interaction terms were created to assess whether these changes over time differed significantly between treatment arms.
For the secondary objective, the outcome variable will be the time to the clinical event. The primary correlate of interest in the analysis of time to clinical event will be the time-updated binary indicator of CD4:CD8 normalization. Kaplan Meier methods for time-dependent covariates will be used to examine the associations of CD4:CD8 normalization with the incidences and rates of survival and selected clinical event. Proportional hazard models will be used to estimate the association of CD4:CD8 normalization with incidences and rates of survival and selected clinical events, after adjusting for other variables hypothesized to be associated with non-AIDS-related events, based on the background literature. When covariates are considered to be collinear (such as IDU and hepatitis C), the variable with the strongest association will be included in the multivariable model. The final model will be adjusted at least by the following variables: age, gender, risk factors for HIV acquisition, year of ART initiation, treatment arm, baseline CD4+ T-cell count and CD8+ T-cell count and time-updated HIV RNA.
For both objectives, sensitivity analyses will be conducted to examine the effects of 1) defining normalization of the CD4:CD8 ratio as >0.5, >0.8, >1 or >1.5, 2) excluding late presenters, defined as having an AIDS-defining events within 3 months after ART initiation and 3) including only patients reaching >500 CD4/uL during follow-up. Missing data will be handled using multiple imputation.
Publication Citation
Serrano-Villar S, Caruana G, Zlotnik A, Pérez-Molina JA, Moreno S. Effects of Maraviroc versus Efavirenz in Combination with Zidovudine-Lamivudine on the CD4/CD8 Ratio in Treatment-Naive HIV-Infected Individuals. Antimicrobial Agents and Chemotherapy. 2017; 61(12). doi: 10.1128/AAC.01763-17.PMID: 28993335.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700350/
© 2024 ideaPoint. All Rights Reserved.
Powered by ideaPoint.
Help
Privacy Policy
Cookie Policy
Help and Resources